

AACR Publications Department

Copyright Transfer Form: *Molecular Cancer Therapeutics*

Cytotoxic effects induced by docetaxel, gefitinib and cyclophosphamide on side population
Title: and non-side population cell fractions from **MS#: MCT- 09-1013**

human invasive prostate cancer cells

The American Association for Cancer Research (AACR), Inc., obtains and owns the copyright to the contents of the journal *Molecular Cancer Therapeutics (MCT)*. Under the terms of Copyright Law PL 94-553, which became effective January 1, 1978, AACR, Inc., must formally obtain transfer of copyright before an article can be published, unless the article was prepared as part of the author's official duties as an employee of the United States Federal Government.

Authors (and all coauthors) who publish in AACR journals retain the right to present orally in any forum all or part of the work and the right to republish parts of the work in any subsequent paper or book of which he/she (or any of the coauthors) is author or editor, subject to the author acknowledging the published source of the material.

AACR, Inc. grants to the author (and all coauthors) permission to deposit their accepted manuscript (after peer review but before editing and formatting) into their institutional repository so long as that repository includes a link to the final version of the article on the AACR journal website (www.aacrjournals.org) and the article is released for public viewing no sooner than 12 months after publication.

Notwithstanding the transfer of copyright to AACR, authors with certain types of research funding may do the following, as outlined below.

NIH Grantees

Authors of manuscripts reporting NIH-funded work that are accepted on or after **April 7, 2008**, are **required** to deposit their unedited and unformatted manuscripts on the National Library of Medicine's PubMedCentral (PMC) database. AACR grants such permission, *without formal request or fee*, subject to the following conditions:

- Only the **accepted manuscript** is deposited, not the edited and formatted paper as published in the journal.
- Authors stipulate that PubMedCentral may release the paper for public access no sooner than **12 months after its print publication date** (the **print publication date** is considered the **official publication date**, not the date of any online publication of earlier versions of the paper).
- Authors **ensure the published source** of the material (the journal citation) is included in the deposited version.
- A link to the final PDF version of the article on the publisher's website (www.aacrjournals.org) is included.

If one or more authors has NIH funding related to this research and is subject to this requirement, please check here.

Howard Hughes Medical Institute (HHMI) Authors

Howard Hughes Medical Institute scientists who are major authors (usually but not always the first or last author) of original research papers submitted to journals after January 1, 2008, are required to deposit their accepted manuscripts on the National Library of Medicine's PubMedCentral (U.S. PMC). The AACR grants such permission, *without formal request or fee*, subject to the following conditions:

- Only the **accepted manuscript** is deposited, not the edited and formatted paper as published in the journal.
- Authors stipulate that PubMedCentral may release the paper for public access not sooner than **6 months after its print publication date** (the **print publication date** is considered the **official publication date**, not the date of any online publication of earlier versions of the paper).
- Authors **ensure the published source** of the material (the journal citation) is included in the deposited version.
- A link to the final PDF version of the article on the publisher's website (www.aacrjournals.org) is included.

If the major author is an HHMI scientist and subject to this requirement, please check here.

Wellcome-Trust, Cancer Research-UK, or UK Medical Research Council Grantees

Authors of manuscripts reporting original research funded by the Wellcome-Trust, Cancer Research-UK, or the UK Medical Research Council and accepted by an AACR journal after October 1, 2006, are required to deposit their articles on UK PubMedCentral (UKPMC), and allow distribution on PMC international mirror sites. Notwithstanding the terms of the AACR copyright transfer form and policies stated herein, AACR grants permission for such deposit, *without formal request or fee*, subject to the following conditions:


- Only the **accepted manuscript** is deposited, not the edited and formatted paper as published in the journal.
- Authors stipulate that UK PubMedCentral may release the paper for public access not sooner than **6 months after its print publication date (the print publication date is considered the official publication date, not the date of any online publication of earlier versions of the paper)**.
- Authors **ensure the published source** of the material (the journal citation) is included in the deposited version.
- A link to the final PDF version of the article on the publisher's website (www.aacrjournals.org) is included.

AACR further recognizes that granting permission to authors to deposit on UKPMC and mirror sites accepted manuscripts reporting work funded by the Wellcome-Trust, Cancer Research-UK, or the Medical Research Council includes permission for such work to be used freely by anyone for non-commercial purposes so long as proper attribution to authors and original publication are made. This permission applies *only to reports of work funded by these agencies* that is accepted for publication in any AACR journal. Commercial purposes are defined, but not limited to, any use that involves the exchange of funds, including resale or funded distribution or use in commercial advertising.

If any one of the authors on this paper is funded by these agencies, please check here.

PLEASE NOTE THAT **ALL** AUTHORS ON THE MANUSCRIPT MUST COMPLETE AND RETURN A COPYRIGHT TRANSFER FORM.

Daniel D. Von Hoff
Editor-in-Chief



In consideration of the fact that AACR, Inc., undertakes to publish my article:

Cytotoxic effects induced by docetaxel, gefitinib and cyclopamine on side
Title (Required): population and non-side poppulation cell fractions from human invasive
prostate cancer cells

Manuscript Number (Required): MCT- 09-1013 in a forthcoming issue of *Molecular Cancer Therapeutics*:

1. I affirm that the material in the above article has not been published previously and that I (and my coauthors) own and have not transferred elsewhere any rights to the article.
2. I affirm that I have obtained written permission to use any previously copyrighted material included in the article and that such documentation will be forwarded to the AACR Publications Department for its files.
3. I hereby assign and transfer to AACR, Inc., all exclusive rights of copyright ownership to the article, including without limitation all rights of reproduction, derivation, distribution, sale, and display of the work, in whole or in part, in any and all forms of media now or hereafter known, as protected by the laws of the United States and foreign countries. These exclusive rights will become the property of the AACR, Inc., from the date of acceptance of the article for publication in the journal *Molecular Cancer Therapeutics*. I understand that AACR, Inc., as copyright owner, has sole authority to grant permission to reproduce the article.

Check the appropriate box(es) below and affix signature(s).

Manuscript # MCT- 09-1013 Title: Cytotoxic effects induced by docetaxel, gefitinib and cyclopamine on side population and non-side population cell fractions from human invasive prostate cancer cells

As authors on this manuscript, we the undersigned individuals transfer copyright of this article to AACR, Inc.

Print Author Name:

Signature:


Date:

Murielle Mimeault




10 december 2009

SONNY L JOHANSSON



10 december 2009

SURINDER K BATHI



December 10, 2009

We, the undersigned individuals, prepared this article as part of our official duties as employee(s) of the company(ies) or commissioning organization(s) listed below and, as duly authorized representative(s) of the indicated company(ies) or commissioning organization(s), hereby transfer copyright of the article to AACR, Inc.

Print Name of Company or Commissioning Organization: _____

Print Author Name:

Signature:

Date:

We, the undersigned individuals, prepared this article as part of our official duties as employee(s) of the United States Federal Government. Therefore, we are unable to transfer rights to AACR, Inc.

Print Author Name:


Signature:

Date:

Fax or E-mail the completed form to: *Molecular Cancer Therapeutics* • Fax: (215) 599-5646 • mct@aacr.org

All authors must sign a copyright transfer form for each article.
If necessary, more than one form may be returned per manuscript.

MCT Fax: (215) 599-5646 • E-mail: mct@aacr.org



Check the appropriate box(es) below and affix signature(s).

Manuscript # MCT- 09-1013 Title: _____


As authors on this manuscript, we the undersigned individuals transfer copyright of this article to AACR, Inc.

Print Author Name:

Signature:

Date:

12 December 2009

JEAN-PIERRE HENICHART 

We, the undersigned individuals, prepared this article as part of our official duties as employee(s) of the company(ies) or commissioning organization(s) listed below and, as duly authorized representative(s) of the indicated company(ies) or commissioning organization(s), hereby transfer copyright of the article to AACR, Inc.

Print Name of Company or Commissioning Organization: _____

Print Author Name:

Signature:

Date:

We, the undersigned individuals, prepared this article as part of our official duties as employee(s) of the United States Federal Government. Therefore, we are unable to transfer rights to AACR, Inc.

Print Author Name:

Signature:

Date:

Fax or E-mail the completed form to: *Molecular Cancer Therapeutics* • Fax: (215) 599-5646 • mct@aacr.org

**All authors must sign a copyright transfer form for each article.
If necessary, more than one form may be returned per manuscript.**

Check the appropriate box(es) below and affix signature(s).


Manuscript # MCT- 09-1013 Title: _____

As authors on this manuscript, we the undersigned individuals transfer copyright of this article to AACR, Inc.

Print Author Name:

Patrick DERREUX

Signature:



Date:

5/12/2009

We, the undersigned individuals, prepared this article as part of our official duties as employee(s) of the company(ies) or commissioning organization(s) listed below and, as duly authorized representative(s) of the indicated company(ies) or commissioning organization(s), hereby transfer copyright of the article to AACR, Inc.

Print Name of Company or Commissioning Organization: _____

Print Author Name:

Signature:

Date:

We, the undersigned individuals, prepared this article as part of our official duties as employee(s) of the United States Federal Government. Therefore, we are unable to transfer rights to AACR, Inc.

Print Author Name:

Signature:

Date:

Fax or E-mail the completed form to: **Molecular Cancer Therapeutics** • Fax: (215) 599-5646 • mct@aacr.org

**All authors must sign a copyright transfer form for each article.
If necessary, more than one form may be returned per manuscript.**